FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 648 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell... January 22, 2026 49-Year-Old Breast Cancer Patient Grateful She Didn’t Wait Until 50 for... June 7, 2019 How My Navy Career Helped Shape My Positive Attitude During My... December 16, 2020 Population Mortality from NSCLC in the US Fell Sharply Due to... August 19, 2020 Load more HOT NEWS Inside Cancer Grand Challenges Part 1: what makes a grand challenge? FDA Recognises OncoKB Database of Molecular Tumour Marker Information Binimetinib Contributes to the Efficacy and Safety Outcomes Observed with Encorafenib... Talazoparib Does Not Prolong OS in BRCA1/2-mutated, HER2-negative Advanced Breast Cancer
